JNDOF Quote, Financials, Valuation and Earnings

PeptiDream Inc. has a net margin of 6.1% compared to Jins Holdings, Inc.'s net margin of -25.38%. Jins Holdings, Inc.'s return on equity of 28.89% beat PeptiDream Inc.'s return on equity of -10.42%.

Jins Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Jins Holdings, Inc. has higher upside potential than PeptiDream Inc., analysts believe Jins Holdings, Inc. is more attractive than PeptiDream Inc..

Jins Holdings, Inc. has a beta of -0.462, which suggesting that the stock is 146.169% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.551, suggesting its less volatile than the S&P 500 by 44.854%.

Jins Holdings, Inc. has a quarterly dividend of $0.40 per share corresponding to a yield of 3.23%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jins Holdings, Inc. pays 30.54% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Jins Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Jins Holdings, Inc. quarterly revenues are $158.6M, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Jins Holdings, Inc.'s net income of $9.7M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Jins Holdings, Inc.'s price-to-earnings ratio is 9.35x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jins Holdings, Inc. is 0.79x versus 11.85x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma Co., Ltd. has a net margin of 6.1% compared to Jins Holdings, Inc.'s net margin of -24.76%. Jins Holdings, Inc.'s return on equity of 28.89% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.

Jins Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Jins Holdings, Inc. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Jins Holdings, Inc. is more attractive than Nxera Pharma Co., Ltd..

Jins Holdings, Inc. has a beta of -0.462, which suggesting that the stock is 146.169% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.011, suggesting its less volatile than the S&P 500 by 98.941%.

Jins Holdings, Inc. has a quarterly dividend of $0.40 per share corresponding to a yield of 3.23%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jins Holdings, Inc. pays 30.54% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Jins Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Jins Holdings, Inc. quarterly revenues are $158.6M, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Jins Holdings, Inc.'s net income of $9.7M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Jins Holdings, Inc.'s price-to-earnings ratio is 9.35x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jins Holdings, Inc. is 0.79x versus 2.48x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Stemcell Holdings, Inc. has a net margin of 6.1% compared to Jins Holdings, Inc.'s net margin of --. Jins Holdings, Inc.'s return on equity of 28.89% beat Stemcell Holdings, Inc.'s return on equity of --.

Jins Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Jins Holdings, Inc. has higher upside potential than Stemcell Holdings, Inc., analysts believe Jins Holdings, Inc. is more attractive than Stemcell Holdings, Inc..

Jins Holdings, Inc. has a beta of -0.462, which suggesting that the stock is 146.169% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Jins Holdings, Inc. has a quarterly dividend of $0.40 per share corresponding to a yield of 3.23%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jins Holdings, Inc. pays 30.54% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Jins Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Jins Holdings, Inc. quarterly revenues are $158.6M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Jins Holdings, Inc.'s net income of $9.7M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Jins Holdings, Inc.'s price-to-earnings ratio is 9.35x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jins Holdings, Inc. is 0.79x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical Co., Ltd. has a net margin of 6.1% compared to Jins Holdings, Inc.'s net margin of -1.05%. Jins Holdings, Inc.'s return on equity of 28.89% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.

Jins Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 9.8%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Jins Holdings, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Jins Holdings, Inc..

Jins Holdings, Inc. has a beta of -0.462, which suggesting that the stock is 146.169% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.019, suggesting its less volatile than the S&P 500 by 98.068%.

Jins Holdings, Inc. has a quarterly dividend of $0.40 per share corresponding to a yield of 3.23%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.05% to investors and pays a quarterly dividend of $0.32 per share. Jins Holdings, Inc. pays 30.54% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Jins Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.

Jins Holdings, Inc. quarterly revenues are $158.6M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Jins Holdings, Inc.'s net income of $9.7M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Jins Holdings, Inc.'s price-to-earnings ratio is 9.35x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 206.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jins Holdings, Inc. is 0.79x versus 1.76x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.